Pharma manufacturing: cooperation for sustainable change

Sustainability is top of the agenda for many pharmaceutical manufacturing companies. Which role do technology providers and their equipment play in reducing CO2 emissions

Synthetic DNA: breaking the bottleneck in genetic medicine manufacturing

Why is the use of synthetic DNA a better choice for emerging genetic medicines?

Innovative manufacturing techniques for gene therapies

What are some innovative techniques used for manufacturing gene therapies at a commercial scale?

Natoli – data collection tips for R&D presses

Tablet formulation development often uses small R&D tablet presses to optimise both the composition of the formulation and manufacturing process parameters. These types of machines have a wide variety of capabilities and may be either single station or small rotaries.

Expertise in fine chemicals, cholesterol/vitamin D manufacturing

CARBOGEN AMCIS’ Manchester, UK, site plays a crucial role in early-phase drug development, providing high-quality starting materials and building blocks across industries, including pharmaceuticals, cosmetics, electronics and dental applications.

World-class drug product capabilities: from formulation to commercialisation

Our expertise in drug product development encompasses a wide range of pharmaceutical services. From formulation design to commercial-scale manufacturing, we specialise in efficiently bringing your drug product to market while ensuring full compliance with regulatory standards. Our highly skilled team at our state-of-the-art facility in Saint-Beauzire, France, ensures that your drug product is manufactured with precision and meets the highest quality standards.

Drug substance: from bench to market

With a strong track record in complex chemistry, CARBOGEN AMCIS offers end-to-end drug substance solutions, from preclinical development to commercial supply.

Driving innovation with purpose: our vision, values and expertise

CARBOGEN AMCIS is a leading global contract development and manufacturing organisation (CDMO), trusted by pharmaceutical and biopharmaceutical companies worldwide. With over 40 years of expertise, the company offers an integrated suite of services across drug substance and drug product development, helping clients to bring life-changing therapies to market with precision and efficiency.

CARBOGEN AMCIS

Cell processing platforms in biologics therapeutics manufacturing

Julien Muzard at Entegris speaks to IPT about how innovations in downstream cell processing platforms will improve biologics therapeutics manufacturing, and the impact artificial intelligence will have on the sector

Multi-tip tooling: a guide

What are some challenges with multi-tip tooling, and how can these be overcome?

Why the pharmaceutical industry is embracing continuous manufacturing

Batch manufacturing has been the standard in the pharma industry, however continuous manufacturing is now proving to be the better choice for efficiency, as well as waste and cost reduction. How can new technologies improve this method further?

Powering pharma innovation: building a workforce for the future

What are some leadership and human resource strategies critical to success in the pharma cdmo sector, including best practices, emerging trends and challenges in managing talent within a highly competitive and evolving industry?

Comprehensive solutions for tablet and capsule manufacturing

Discover how natoli engineering empowers the pharmaceutical industry with innovative equipment, expert training, and unparalleled customer support and expertise. We are the global leader in tablet compression tooling. Our commitment to the tablet compression industry is demonstrated through the development of groundbreaking solutions and progressive, continual improvements in our manufacturing processes. Partner with us – we are better together!

Hand-in-hand: good manufacturing practice and stability studies

Following good manufacturing practices (GMP) is crucial for stability testing. The analytical data generated from stability studies is a pivotal part of a regulatory dossier submission to substantiate the shelf life claimed for the drug product or drug substance and further support that shelf-life post-approval. All aspects of the stability study must be executed to the highest level of quality to ensure...

The regulatory headache: advanced monitoring technologies can provide pain relief

Focusing on regulation within pharmaceutical manufacturing can help re-centre a company’s priorities, while ensuring compliance. This can be aided by the use of advanced monitoring techniques

From legacy systems to sample automation: managing a successful transition to high-density cold samp

As the need for ultra-low temperature sample storage rises, many labs are stuck expanding outdated ‘freezer farms’ to meet demand. High-density automated cold storage offers a smarter, more efficient solution, but reaping the benefits depends on more than the technology itself – it requires thoughtful change management. How can companies approach change management to drive lasting adoption and maximise the value of automation?

Smart resource strategy: optimising lab assets in pharma

In an era of cost-conscious innovation, including tighter budgets, talent shortages and escalating regulatory demands, life sciences labs are under pressure to improve performance while managing budgets more wisely. By focusing on equipment utilisation and asset intelligence, labs can reduce downtime, avoid unnecessary purchases, optimise maintenance intervals and scale smarter – all without compromising quality or compliance

Robotic automation in the pharma lab

IPT talks to Roya Amini-Naieni at Trilobio about robotic automation in pharma research, the different applications of soft-and hardware, and how the field is likely to develop over the next five years

Automated labs: the future of drug R&D

IPT talks to David Fuller at Artificial Inc about how automated labs are revolutionising the pharma R&D space by connecting disparate systems, easing the burden of manual tasks on workers, and speeding up time-to-market with tools such as artificial intelligence

Rapid microbiological monitoring: transforming environmental monitoring in pharma manufacturing

Ensuring a manufacturing environment stays clear of bacteria and fungi is of utmost importance, especially when it comes to pharmaceuticals. How can this highly specialised monitoring be achieved in a fast, cost-effective manner?

One cannot leverage AI without a connected laboratory

A connected laboratory, where systems and devices communicate seamlessly, is the foundation to unlock AI’s full capabilities

The journey to full automation – for labs of all sizes

With the lab of the future becoming increasingly automated, how will this change workflows and how can the industry prepare for this?

Bridging the gap: Integrating legacy equipment for modular production

The pharmaceutical sector is characterised by intricate processes, stringent regulations and a constant demand for innovation. However, the industry's digital transformation is hindered by the prevalence of legacy machinery, which often poses compatibility challenges when deploying new technology. COPA-DATA explains the method of standardisation to remove the barriers of integration of legacy equipment in labs and production lines

Lab automation: the future of life sciences

'Increasing economic challenges like market vitality, product diversification and cost pressure lead to the need for faster process design' − and that is not to mention the shorter innovation cycles and increasing demand for small batch production. The module type package suite from COPA-DATA meets these needs

Automation holds the key to unlocking the Lab of the Future

Lab layouts, until the introduction of automation, had seen little change in decades. However, the increased usage of hardware and software lab automation has reduced repetitive manual tasks and drastically increased the walkaway time involved in experiments

Five Steps to Successful AI

Whether lab managers are enthusiastic or apprehensive, AI is coming to the lab. The key to building this advantage is not in the technology, but the approach. Successful adoption of AI requires a genuine, long-term commitment. IPT spoke to Bob Voelkner at LabVantage Solutions about the implications of AI for pharma, what it takes to succeed with this new technology and his five recommended steps for getting started

LabVantage Solutions Company Profile

LabVantage Solutions’ Pharmaceutical LIMS is Engine for Digital Transformations

The Importance of Network Integration for Measurement and Hygiene Technology Solutions

Healthcare and scientific facilities are critical for the health of the global population. During the COVID-19 pandemic, scientific facilities helped to deliver life-saving vaccines, re-emphasising their importance in achieving other scientific milestones in the coming decades

Next-Level Digitalisation: Smart Pharma Production Gets Even Smarter

The digitalisation of pharmaceutical manufacturing has come a long way. However, there are still many ways companies can improve systems to grow even further

Three Lessons Pharma Can Learn From Manufacturing to Become a Leader in Automation

Pharmaceutical companies face plenty of challenges throughout the manufacturing cycle. Automation can be the key to bringing the industry to the forefront of this exciting field

AI, 3D Reconstruction, and Robotics in Clinical Phlebotomy

IPT speaks to Toon Overbeeke of Vitestro about the potential benefits of using robots in clinics to draw blood from patients. With a shortage of clinical staff all over Europe, Toon believes robotics is the way forward regarding individual clinical patient care